Press Room

RDD Europe 2019

Start
Tuesday, May 07, 2019 - 09:00
End
Friday, May 10, 2019 - 17:00
Location: Lisbon, Portugal
Booth Number: Table nr. 64

RDD Europe 2019 will be held at the Estoril Congress Center in Portugal and Hovione will be present.

 

Hovione, together with Hovione Technology will present an interactive workshop session:
 

Fully Integrated Dry Powder Solutions

  • Wednesday, May 8th | 2:00pm, 3:15pm and 4:30pm – Room F7
  • Presented by: Beatriz Fernandes, M.Sc., Eunice Costa, Ph.D., João Ventura, Ph.D.and Maria Braga, Ph.D.

This session will review traditional and advanced formulation approaches for inhalation and nasal delivery, coupling key aspects across particle engineering as well as formulation and device design. Case studies will be presented focused on the interaction between traditional carrier-based formulation components and the final outcome in terms of aerodynamic performance, manufacturability and expected lung dose. Further case studies will look at carrier-free formulations for DPIs and for nasal applications, advanced particle engineering technologies applicable to labile biomolecules and finally design optimization of a cost-effective capsule-based inhaler and device development targeting high dose delivery.
 
Hovione will also have two Communications:
 
May 9, 2019 | 11:00 am

  • Spray Drying of Inhalable Biopharmaceuticals of Increasing Size and 3D Structure Complexity: From 30 to 250 kDa (Session 4: Poster in the podium)
    Diana Fernandes, M.Sc., Hovione, Loures, Portugal

 
May 10, 2019 |11:15 am

  • Continuous Processing: Challenging the Current Manufacturing Paradigm for Dry Powder Inhalers (Session 7: New Approaches to Inhalation Product Development and Production)
    Eunice Costa, Ph.D., Hovione, Loures, Portugal

 

If you would like to discuss with us your projects and to find how Hovione can help, schedule a meeting with us. Our team will be pleased to meet you.

 

 

 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026